Inhaled steroids and mortality in COPD: bias from unaccounted immortal time

Kiri V.A., Vestbo J., Pride N.B., Soriano J.B.

Source: Eur Respir J 2004; 24: 190-191

Journal Issue: July

Disease area: Airway diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kiri V.A., Vestbo J., Pride N.B., Soriano J.B.. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004; 24: 190-191

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Inhaled steroids and mortality in COPD: bias from unaccounted immortal time Source: Eur Respir J 2004; 23: 391-395 Year: 2004
Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias? Source: Eur Respir J, 53 (2) 1802112; 10.1183/13993003.02112-2018 Year: 2019
Inhaled beta2-agonists and death for asthma: can we overcome this risk? Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths Year: 2007
Inhaled corticosteroids in COPD: a case in favour Source: Eur Respir J 2009; 34: 10-12 Year: 2009
Inhaled corticosteroid containing combinations and mortality in COPD Source: Eur Respir J, 52 (6) 1801230; 10.1183/13993003.01230-2018 Year: 2018
Inhaled corticosteroids in COPD: the case against Source: Eur Respir J 2009; 34: 13-16 Year: 2009
Inhaled therapy reduces COPD mortality Source: ERJ Open Res, 6 (4) 00634-2020; 10.1183/23120541.00634-2020 Year: 2020
Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019 Year: 2019
Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019 Year: 2019
Inhaled corticosteroid therapy reduces the risk of rehospitalization and all-cause mortality in elderly asthmatics Source: Eur Respir J 2001; 17: 380-385 Year: 2001
The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015
Inhaled corticosteroids in COPD: the clinical evidence Source: Eur Respir J 2015; 45: 525-537 Year: 2015
Inhaled corticosteroids in COPD: the final verdict is… Source: Eur Respir J, 52 (6) 1801940; 10.1183/13993003.01940-2018 Year: 2018
Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD Source: Annual Congress 2012 - COPD: risk factors, biomarkers and diagnosis Year: 2012
Inhaled steroids and COPD Source: Eur Respir J 2008; 32: 523-524 Year: 2008
Inhaled corticosteroid use and the incidence of lung cancer in COPD Source: Eur Respir J, 55 (2) 1901720; 10.1183/13993003.01720-2019 Year: 2020
Inhaled steroids in exacerbations of COPD Source: Eur Respir J 2007; 30: 398 Year: 2007
Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD Source: Eur Respir J 2010; 36: 494-502 Year: 2010
Inhaled corticosteroid related pneumonia in real world among the patients with asthma and COPD Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Weaning from inhaled corticosteroids in COPD: the evidence Source: Eur Respir J 2015; 46: 1232-1235 Year: 2015